Lymphoid subsets in the thymus and spleen from ADA–/– GT- and BMT-treated mice at 6 months after treatment
. | . | Thymus, % positive cells ± SD . | . | . | . | Spleen, % positive cells ± SD . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | N . | CD4-CD8- . | CD4+CD8+ . | CD4+CD8- . | CD4-CD8+ . | CD3+CD4+ . | CD3+CD8+ . | B220+IgM+ . | |||||
| ADA-/- GT | 5 | 3.8 ± 1.3 | 73.8 ± 5.5 | 16.2 ± 3.3 | 6.0 ± 1.4 | 29.6 ± 8.8 | 7.1 ± 1.7 | 17.8 ± 4.3 | |||||
| ADA-/- BMT | 5 | 4.7 ± 4.2 | 74.0 ± 6.4 | 16.0 ± 4.3 | 4.8 ± 0.6 | 22.8 ± 6.6 | 6.8 ± 2.2 | 15.0 ± 9.2 | |||||
| ADA+/+ untreated | 7 | 2.8 ± 0.3 | 83.0 ± 1.4 | 10.0 ± 1.0 | 3.3 ± 0.4 | 21.6 ± 3.8 | 8.7 ± 2.7 | 12.2 ± 5.3 | |||||
| ADA-/- untreated* | 6 | 13.8 ± 12.0 | 77.0 ± 11.0 | 4.9 ± 1.6 | 3.5 ± 0.8 | 2.1 ± 1.2 | 1.4 ± 0.9 | 4.0 ± 1.8 | |||||
. | . | Thymus, % positive cells ± SD . | . | . | . | Spleen, % positive cells ± SD . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | N . | CD4-CD8- . | CD4+CD8+ . | CD4+CD8- . | CD4-CD8+ . | CD3+CD4+ . | CD3+CD8+ . | B220+IgM+ . | |||||
| ADA-/- GT | 5 | 3.8 ± 1.3 | 73.8 ± 5.5 | 16.2 ± 3.3 | 6.0 ± 1.4 | 29.6 ± 8.8 | 7.1 ± 1.7 | 17.8 ± 4.3 | |||||
| ADA-/- BMT | 5 | 4.7 ± 4.2 | 74.0 ± 6.4 | 16.0 ± 4.3 | 4.8 ± 0.6 | 22.8 ± 6.6 | 6.8 ± 2.2 | 15.0 ± 9.2 | |||||
| ADA+/+ untreated | 7 | 2.8 ± 0.3 | 83.0 ± 1.4 | 10.0 ± 1.0 | 3.3 ± 0.4 | 21.6 ± 3.8 | 8.7 ± 2.7 | 12.2 ± 5.3 | |||||
| ADA-/- untreated* | 6 | 13.8 ± 12.0 | 77.0 ± 11.0 | 4.9 ± 1.6 | 3.5 ± 0.8 | 2.1 ± 1.2 | 1.4 ± 0.9 | 4.0 ± 1.8 | |||||
No statistically significant differences were observed among ADA-/- GT and ADA-/- BMT and adult untreated ADA+/+ mice in all categories, with the exception of CD3+CD4+ splenocytes, which were higher in GT mice (P < .05; post-hoc analysis with Bonferroni correction).
Thymus and spleen from untreated ADA-/- mice were collected 18 days after birth.